Joe Anderson has been reappointed chief executive officer of Arix Bioscience Plc, a healthcare investor, following a six-month period as the group’s chief investment officer. Dr Anderson is a former pharmaceutical analyst as well as a partner of Abingworth. He received a BSc in biological science at Queen Mary College, University of London and a PhD in biochemistry from the University of Aston, UK. Arix also announced the retirement of Christopher Evans, a leading biotechnology entrepreneur, from its board of directors.
Arix Bioscience announced the management changes on 19 February 2019.
Copyright 2019 Evernow Publishing Ltd